Galmed Develops Innovative LNP Formulation of Aramchol Targeting Heart Diseases

In a noteworthy advancement in biopharmaceuticals, Galmed Pharmaceuticals Ltd. has joined forces with Barcode Nanotech to introduce a novel formulation of Aramchol, an SCD1 inhibitor, using lipid nanoparticles (LNPs). This formulation is designed to enhance the biodistribution of Aramchol, directing it toward cardiac tissue instead of the liver, a significant shift given the traditional formulation's tendency to accumulate in liver cells by 80-90%.

This new targeted approach is particularly crucial as cardiac fibrosis is recognized as a significant contributor to chronic heart failure, which is projected to cause approximately 20.5 million deaths by 2025. Galmed's innovative formulation aims to address a pressing unmet medical need, providing a potential disease-modifying therapy for cardiac conditions.

The Galmed team has leveraged advanced formulation science, in vivo screening, and AI capabilities to optimize the delivery of Aramchol to the heart. The collaboration with Barcode Nanotech has opened avenues for developing targeted therapies that can efficiently engage relevant cardiac cell populations, including fibroblasts, vital to combating heart diseases. This cooperative platform, featuring an in vivo screening methodology, allows the examination of various nanoparticle candidates to identify formulations with enhanced targeting and functional performance.

Allen Baharaff, co-founder and CEO of Galmed, expressed enthusiasm for the potential of this innovative approach, emphasizing the company's commitment to creating transformative medicines and technologies across various health domains, particularly GI oncology and cardiometabolic diseases. This collaboration furthers Galmed's goal of exploring groundbreaking therapeutic candidates, aiming to position the company at the forefront of drug development and innovation.

Meanwhile, Ronen Eavri, co-founder and CEO of Barcode Nanotech, shed light on their unique library of lipids for RNA and DNA delivery through a cutting-edge, AI-based mass screening platform, highlighting the efficiency and potential of their collaborative efforts with Galmed. This synergy could pave the way for a new generation of cardiac therapies, beginning with the Aramchol formulation.

With cardiovascular diseases remaining a leading cause of mortality globally, the development of effective treatments for cardiac fibrosis is imperative. Although advancements in cardiovascular care have been made, there currently exist no therapies capable of preventing or reversing cardiac fibrosis. Galmed's novel approach, targeting the heart tissue directly, represents a significant leap toward fulfilling this medical demand.

In summary, the partnership between Galmed Pharmaceuticals and Barcode Nanotech signifies a transformative step in addressing cardiac diseases through innovative drug delivery systems. As the companies continue their research and development efforts, the anticipation around Aramchol’s new formulation grows, holding promise for many patients needing advanced therapeutic options.